Passive-active immunoprophylaxis for all infants born from HBeAG-negative chronic HBV-infected mothers: Is it a cost-effective strategy?

Hepatology Research

Volumn 37, Issue 7, 2007, Pages 577-578

  Elefsiniotis, Ioannis S ^a   Papadakis, Miltiadis A ^a   Vlahos, George ^a   Antsaklis, Aris ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ACTIVE IMMUNIZATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFANT DISEASE; LETTER; MOTHER CHILD RELATION; NONHUMAN; PASSIVE IMMUNIZATION; PERINATAL INFECTION; PRIORITY JOURNAL; SEROLOGY; VERTICAL TRANSMISSION; VIRUS REPLICATION;

EID: 34249883859     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00075.x     Document Type: Letter

References (9)

1. Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis from preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg-positive mothers in comparison with vaccine alone. Hepatol Res 2006; 36: 265-71.
2. Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: Aspects on vertical transmission. Scand J Infect Dis 2003; 35: 814-19.
3. Wang Z, Zhang J, Yang H et al. Quantitative analysis of HBV-DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003; 71: 360-6.
4. Elefsiniotis IS, Glynou I, Magaziotou I et al. HBeAg negative serological status and low viral replication levels characterize chronic hepatitis B virus-infected women at reproductive age in Greece: A one-year, prospective single-center study. World J Gastroenterol 2005; 11: 4879-82.
5. Hadziyannis S, Papatheodoridis G. Hepatitis B e antigen negative chronic hepatitis B: Natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
6. Papadakis M, Elefsiniotis IS, Vlachos G, Daskalakis G, Barbatis C, Antsaklis A. Intrauterine-transplacental transmission of hepatitis B virus from hepatitis B e antigen negative (precore mutant, G1896A) chronic HBV infected mothers to their infants. J Clin Virol 2007; 38: 181-2.
7. Yang YJ, Liu CC, Chen TJ et al. Role of hepatitis B immunoglobulin in infants born to hepatitis B e antigen-negative carrier mothers in Taiwan. Pediatr Infect Dis J 2003; 22: 584-8.
8. Milne A, West DJ, Chinh DV, Moyes CD, Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002; 67: 327-33.
9. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 1999; 29: 1252-8.